

**CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)**

I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service

- ☒ as first class mail, postage prepaid (37 C.F.R. § 1.8)  
☐ "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10  
Express mail label mailing number:

on the date inserted below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Lynette Eliason  
Typed name of person mailing transmittal

December 8, 1999  
Date of Deposit

Lynette Eliason  
Signature of person mailing transmittal

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner: S. Devi, Ph.D.

Group Art Unit No.: Beekman et al.

Applicant(s): Beekman et al.

Filing date: May 7, 1999

Serial No.: May 7, 1999

For (title): VACCINE COMPRISING ANTIGENS BOUND TO  
CARRIERS THROUGH LABILE BONDS



Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**RECEIVED**

DEC 21 1999

TECH CENTER 1600/2900

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

- ☒ Postcard receipt acknowledgment (attached to the front of this transmittal).  
☒ Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fees may be charged to deposit account no. 20-1469.  
☐ Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.  
☐ Preliminary amendment.  
☒ Amendment or other communication in response to the non-final office action mailed November 8, 1999.  
☐ Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed .  
☐ Petition for Extension of Time in duplicate with check no. in the amount of \$.  
☐ Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of) .  
☐ Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.  
☒ Substitute Drawing (Fig. 1); Copy of notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures; Statement under 37 C.F.R. §§ 1.821(g) and 1.825; Paper copy of sequence listing; and CRF copy of sequence listing.

**Remarks:**

- ☐ An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

	1	2	3	EXTRA
Total claims	-	=	x 18.00 =	
Indep. claims	-	=	x 78.00 =	
First presentation of a multiple dep. claim (+260.00)				
<b>SUBTOTAL</b>				
Reduction for small entity - 50% of subtotal*				
<b>TOTAL ADDITIONAL FEE (subtotal minus any reduction)</b>				

\*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

- 1 Claims remaining after amendment.  
2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.  
3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

- ☒ The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.

Respectfully submitted,

Allen C. Turner  
Reg. No. 39,931

For:

Allen C. Turner  
Reg. No. 33,041  
TRASK, BRITT & ROSSA  
P.O. Box 2550  
Salt Lake City, UT 84110-2550  
(801) 532-1922

Date: December 8, 1999  
Enclosures: As identified above

**RECEIVED**

DEC 16 1999

TECH CENTER 1600/2900